Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9771399 | 1.00 | LMNA (0.46) | LMNABLMPTPN1ALDH1A1MEN1 | |
| SCHEMBL812730 | 0.94 | LMNA (0.46) | LMNABLMALDH1A1HIF1AEPAS1 | |
| SCHEMBL2870971 | 0.93 | LMNA (0.59) | LMNABLMPTPN1ALDH1A1MEN1 | |
| SCHEMBL132754 | 0.93 | LMNA (0.59) | LMNABLMPTPN1ALDH1A1MEN1 | |
| SCHEMBL17629435 | 0.93 | LMNA (0.59) | LMNABLMPTPN1ALDH1A1MEN1 | |
| SCHEMBL11764634 | 0.92 | LMNA (0.43) | LMNABLMALDH1A1HIF1AEPAS1 | |
| SCHEMBL1786679 | 0.92 | LMNA (0.43) | LMNABLMALDH1A1HIF1AEPAS1 | |
| SCHEMBL28617279 | 0.91 | TSHR (0.36) | LMNATSHRSMN1; SMN2ADH1BADH1C | |
| SCHEMBL18092228 | 0.85 | LMNA (0.56) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL6740341 | 0.85 | TSHR (0.36) | LMNATSHRSMN1; SMN2ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113873884-B | Arthropod control composition | 弗门尼舍有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118043442-A | Solid soluble compositions | 宝洁公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117999336-A | Low water content compositions | 宝洁公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117999337-A | Low water content compositions | 宝洁公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117980458-A | Low water content compositions | 宝洁公司 | 2024-05-03 | — | — | CN | claimed |
| CN-117940547-A | Solid soluble compositions | 宝洁公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117916356-A | Solid soluble compositions | 宝洁公司 | 2024-04-19 | — | — | CN | claimed |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-12-19 | — | — | US | claimed |
| CN-113873884-A | Arthropod control composition | 弗门尼舍有限公司 | 2021-12-31 | — | — | CN | claimed |
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-18 | — | — | US | claimed |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-21 | — | — | US | claimed |
| CN-113056547-A | Jasmine alcohol | 西姆莱斯有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-108054283-B | Molybdenum trioxide anode interface layer with insensitive film thickness, preparation method thereof and application thereof in organic solar cell | 中国科学院化学研究所 | 2021-03-05 | — | — | CN | claimed |
| EP-2830438-B1 | N-ACYL DERIVATIVES OF GAMMA AMINO-BUTYRIC ACID AS FOOD FLAVOURING COMPOUNDS, POWDER COMPOSITIONS CONTAINING THEM | GIVAUDAN SA (CH) | 2019-09-04 | — | — | EP | claimed |
| EP-2478355-B1 | METHODS FOR DETECTING AUTODIGESTION | UNIV CALIFORNIA (US) | 2018-11-14 | — | — | EP | claimed |
| US-20140323572-A1 | Antimicrobial Mixture of Aldehydes, Organic Acids and Fatty Acid Esters | ANITOX CORP. | 2014-10-30 | — | — | US | claimed |
| EP-2785205-A1 | ANTIMICROBIAL MIXTURE OF ALDEHYDES, ORGANIC ACIDS AND ORGANIC ACID ESTERS | Anitox Corporation (US) | 2014-10-08 | — | — | EP | claimed |
| WO-2013081777-A1 | ANTIMICROBIAL MIXTURE OF ALDEHYDES, ORGANIC ACIDS AND ORGANIC ACID ESTERS | ANITOX CORPORATION (US) | 2013-06-06 | — | — | WO | claimed |
| US-20120115177-A1 | Compositions and Methods for Diagnosis of Shock | ANAZYME, LLC (US) | 2012-05-10 | — | — | US | claimed |
| WO-2010087874-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OF SHOCK | ANAZYME, LLC (US) | 2010-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | LMNA 2477/4885BLM 3348/4885PTPN1 4604/4885 |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | LMNA 2551/4885BLM 3418/4885PTPN1 4636/4885 |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | LMNA 2551/4885BLM 3418/4885PTPN1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.